Zorginstituut Nederland (ZIN), EUnetHTA and Belgian Health Care Knowledge Centre (KCE), EUnetHTA (2018): MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EUnetHTA report . HTA-Projektbericht 102.